Search

everythinglearnresearchcommunity

for

Search:↓

Topical sodium valproate may promote hair growth by inhibiting GSK3β, allowing beta-catenin to proliferate, but it has potential side effects and requires more research. The conversation also mentions skepticism about a product called Vdphlo1, which includes sodium valproate and other ingredients.

The user reports hair regrowth at the crown and thickening at the front after three months using 1mg finasteride, 0.5% minoxidil, biotin supplements, vitamin D, and argan oil shampoo and conditioner. They express a wish that hair growth could occur at the back of the head as well.

The clinic diagnosed the user with NW3 and AGA, noting thinning hair despite using finasteride for 3 years, and suggested PRP and Mesotherapy before considering a transplant. The user questions the necessity of these treatments without confirming retrograde alopecia and its treatability.

Treatments for hair loss, such as Minoxidil, finasteride, RU58841 and Eucapil; the legitimacy of RU58841 products; and safety concerns related to using RU58841.

The conversation is about using distilled water as a solvent for topical finasteride to reduce systemic absorption. The user is considering avoiding ethanol and propylene glycol to achieve this.

A new hair growth product claims to use apple stem cells, plant collagen, and bamboo leaf extract, with a 120-day money-back guarantee. Some users are skeptical, noting the product's marketing alongside other treatments like Minoxidil, finasteride, and red light therapy.

RU58841, combined with 5% minoxidil, helped reduce acne and hair loss. Users discussed using RU58841 cream for acne and shared experiences with other treatments like finasteride and dutasteride.

The user shared a 3-year hair restoration update using 0.5mg dutasteride daily, 5% minoxidil foam twice daily, a 1.5mm derma roller twice a month, and Nizoral shampoo. They reported significant improvement and maintenance of hair, with minimal side effects, and are satisfied with the results at age 40.

Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. User seeks upcoming Fluridil group buys.

The conversation is about the effectiveness of a hair loss treatment product containing 0.01% Latanoprost, with the user considering trying it as a vehicle for RU58841. The user questions whether the dosage is too low to be effective.

The conversation is about the timeline for Kintor's phase 3 trials for GT20029 and the potential release of the product in three years. It also mentions treatments like Minoxidil, finasteride, and RU58841.

Topical finasteride with hydroxypropyl chitosan shows significantly less serum absorption and minimal DHT reduction compared to oral finasteride. Users need the specific chitosan formulation to avoid side effects seen with regular ethanol+PG solutions.

The user is experiencing slow but noticeable hair regrowth using 1mg finasteride daily, 5% minoxidil, microneedling, and vitamins. They have also adopted healthier lifestyle habits and are considering a hair transplant in the future.

A user shared their 3-year progress using 1mg finasteride and 5% topical minoxidil twice daily, reporting significant hair regrowth and some side effects like bloating, seborrheic dermatitis, and water retention. The user is happy with the results, noting improvements in both the crown and hairline.

Minoxidil can cause dark circles and skin issues, and users suggest reducing dosage or switching to foam. Supplements like vitamin C, glycine, and MSM may help with collagen production to reduce these side effects.

Low Dose Naltrexone (LDN) may reduce inflammation in alopecia conditions. It is discussed as a potential adjunct treatment with finasteride or dutasteride for androgenic alopecia.

People are discussing the anticipated release of PP405 phase 2a results, expected by the end of March, with some skepticism about its effectiveness. There is cautious optimism due to past experiences with similar treatments like Breezula, despite concerns about the lack of presentation at the AAD 2026 conference.

The user does not respond well to minoxidil and is seeking an alternative to Tretinoin to upregulate sulfurtransferase activity for hair loss treatment. No specific alternative treatments were mentioned.

The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.

Pyrilutamide did not show effectiveness in regrowing hair compared to a placebo, but it may still help maintain existing hair by preventing DHT from causing follicle miniaturization. Some users believe it could be beneficial when used with other treatments like minoxidil, finasteride, and dutasteride.

Adding non-prescription topicals like alfatradiol and Zix to a standard fin/min/niz regimen may help with scalp inflammation and shedding, but their long-term effectiveness varies. Zix is recommended for reducing scalp inflammation and enhancing the effectiveness of other treatments.

Concerns about CosmeRNA safety mechanisms and potential side effects. Discussion includes comparisons to Fluridil and questions about nanoparticle specificity and siRNA stability.

The use of PRP to treat hair loss and its potential effectiveness when combined with 5 alpha reductase blockers such as Minoxidil or Finasteride.

The discussion is about using ASCEplus HRLB exosomes for hair loss treatment, which combines 10 billion exosomes with growth factors, nutrients, biotin, and copper tripeptide. The treatment is expensive and typically administered via scalp injections, but in Europe, it's done with microneedling.

A 25-year-old shared their 3-month progress using a combination of 1mg finasteride and 5% minoxidil for hair loss. The images show noticeable improvement in hair density.

The conversation is about using Xeljanz for hair regrowth in individuals with LPP. The user is seeking experiences and expectations from others who have tried this treatment.

Minoxidil is discussed for hair loss treatment. Cucumber and potato are mentioned for dark circles.

The user is concerned about safely using RU58841 around cats and wonders if applying it 2 hours before a shower is as effective as leaving it overnight. The discussion focuses on the absorption time and effectiveness of RU58841.

PP405 is the most promising future treatment for hair loss, aiming to reactivate dormant hair follicles. Clascoterone 5% is the most promising near-term drug, while current strategies include using finasteride or dutasteride to stabilize hair loss and minoxidil to stimulate growth.

The conversation discusses the potential release of Winlevi in 2019 by Cassiopeia for hair loss treatment. It suggests a regimen combining minoxidil, Winlevi, Nizoral, and possibly dermarolling, with a comment mentioning Breezula as an alternative to finasteride without side effects.